Q-omics provides the consensus-scored CXCL11 profile across patient tissues and cancer cell-line models. CXCL11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CXCL11 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CXCL11 RNA expression shows 14,927 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, HNSC, and UVM as cancer lineages where CXCL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL11 survival associations across molecular data types. CXCL11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL11 RNA expression–survival associations across cancer types. High CXCL11 expression shows unfavorable associations in UVM, KIRP and LGG, but favorable associations in SKCM, OV and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CXCL11 RNA expression.
This table summarizes CXCL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CXCL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL11 shows higher tumor expression in HNSC, KIRC, COAD, STAD, BLCA and BRCA. The HNSC box plot shows higher CXCL11 RNA expression in tumor versus normal tissue (log2 FC = +3.153, t-test p < 0.001).
This table shows molecular features associated with CXCL11 in patient tissues and cancer cell lines. In patient samples, CXCL11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
